Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 32 от 222

Recruiting Phase 2

B7981119 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa

HIDRADENITIS SUPPURATIVA

Trial status: Authorised HiSCR50 response at Weeks 1, 2, 4, 6, 8, and Week 12., HiSCR75 response at Weeks 1, 2, 4, 6, 8, 12 and Week 16., HiSCR90 response at Weeks 1, 2, 4, 6, 8, 12 and Week 16., Response based on a total abscess and nodule (AN) count of 0 or 1 at Week 16., Response based on a total AN count of 0, 1, or 2 at Week 16., Percent (%) change from baseline (CFB) in total AN count at Weeks 1, 2, 4, 6, 8, 12 and 16., Absolute score and CFB in HS-IGA at Weeks 1, 2, 4, 6, 8, 12 and 16., Response based on achieving a HS-IGA=0 or 1 at Weeks 1, 2, 4, 6, 8, 12 and 16., Participants who experience an HS flare, defined as at least a 25% increase in total AN count with a minimum increase of 2 relative to Baseline, at Weeks 4, 8, 12 and 16., CFB in Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) at Weeks 1, 2, 4, 6, 8, 12 and 16., Skin pain NRS30 response, at worst and on average, respectively, at Weeks 1, 2, 4, 6, 8, 12, and 16, among participants with baseline skin pain numeric rating scale (NRS) ≥3., %CFB in skin pain NRS, at worst and on average, respectively, in participants with baseline skin pain NRS ≥3, at Weeks 1, 2, 4, 6, 8, 12, and 16., CFB in skin pain NRS, at worst and on average, respectively, at Weeks 1, 2, 4, 6, 8, 12, and 16., Skin pain NRS50 response, at worst and on average, respectively, at Weeks 1, 2, 4, 6, 8, 12, and 16, among participants with baseline skin pain NRS ≥3., Skin pain NRS70 response, at worst and on average, respectively, at Weeks 1, 2, 4, 6, 8, 12, and 16, among participants with baseline skin pain NRS ≥3., Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation, Incidence of clinically significant laboratory abnormalities over time, Absolute score and CFB in Hidradenitis Suppurativa Quality of Life (HiSQOL) at Weeks 1, 2, 4, 6, 8, 12 and 16., Absolute score and % CFB in IHS4 at Weeks 1, 2, 4, 6, 8, 12 and 16. HiSCR50 response at Week 16

Начало: 11.03.2026 Възраст: от 18 г.

Germany, Greece, Poland +1 Pfizer Inc. 2025-522705-37-00

Recruiting Phase 2

A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of RSS0343 tablets in patients with COPD. The study includes 3 study periods: a 4-week screening period, a 48-week treatment period, and a 4-week follow-up period. The primary endpoint is the annualized rate of moderate or severe exacerbations of COPD during the 48-week treatment period.

Начало: 10.03.2026 Край: 01.04.2028 Възраст: 40–80 г.

China Reistone Biopharma Company Limited NCT07349524

Recruiting Phase 1

A Study of BGM-2121 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.

Начало: 10.03.2026 Край: 01.12.2028 Възраст: от 18 г.

Taiwan BioGate Precision Medicine Corp. NCT07346846

Recruiting

Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups and Individualized Services

Language Delay Substance Use Disorders Language Disorders in Children Language Development +1

The goal of this clinical trial is to test ways to improve early language development among young children of parents with substance use disorder (SUD). Children of parents with SUD are at increased risk for language delays, and early supports may help prevent long-term learning challenges. This study will examine whether adding additional supports to group-based parenting intervention improves child language outcomes compared to the group intervention alone.

Начало: 10.03.2026 Край: 30.11.2029 Възраст: от 18 г.

United States University of Oregon NCT07529327

Recruiting

Efficacy of Behavioral Therapy for Chronic Refractory Cough

Chronic Cough

Chronic cough is defined as cough persisting for more than eight weeks. It is a common clinical problem that significantly impairs patients' physical, psychological, and social quality of life. Chronic cough remains a diagnostic and therapeutic challenge despite systematic evaluation and treatment of common etiologies such as asthma, gastroesophageal reflux disease

Начало: 10.03.2026 Край: 10.05.2027 Възраст: 18–50 г.

Egypt Assiut University NCT07488598

Recruiting

Effects of Stoma Education on Patients

Colostomy - Stoma Ileostomy - Stoma Patient Education Body Image +2

tomas are classified according to the anatomical region in which they are created and the surgical technique used. Stomas that open into the large intestine are called colostomies, those that open into the small intestine are called ileostomies, and the creation of an anastomosis of the ureters to the abdominal wall is called a urostomy. Stomas are commonly used in the treatment of gastrointestinal diseases. Ileostomy and colostomy are the most frequently encountered types of stomas. While colorectal cancer is the primary reason for intestinal stoma creation, inflammatory bowel diseases, penetrating abdominal injuries, congenital anomalies, obstructions due to diverticular disease, ischemic colitis, radiation injury, sigmoid colon volvulus, and fecal incontinence are also among the indications for stoma creation. Despite advances in surgical techniques, complications are commonly seen in individuals with stomas. Incorrect stoma placement, the use of inappropriate bags and adapter systems, and a lack of knowledge and skills among patients and caregivers play a significant role in the development of complications. Depending on these conditions, patients may encounter problems such as edema, bleeding, ischemia, and mucocutaneous dehiscence in the early postoperative period. These complications negatively affect not only physical health but also the individual's social life, psychological state, and overall quality of life. Symptoms such as peristomal skin problems, uncontrolled gas release, fecal incontinence, and pain can hinder participants' adaptation to daily life and lead to social isolation. Nursing care and patient education are of great importance in managing these problems faced by individuals with stomas. The nursing process requires a comprehensive approach extending from the pre-operative period to the post-discharge phase. In this process, individualized education programs addressing fundamental issues such as nutrition, elimination, sexuality, social participation, and privacy should be implemented to improve quality of life, develop self-care skills, and prevent complications. In this context, the investigators have planned this study to determine the effects of the education provided to patients on stoma adaptation, body image, and self-efficacy.

Начало: 10.03.2026 Край: 10.08.2026 Възраст: 18–90 г.

Turkey (Türkiye) Ataturk University NCT07464548

Recruiting

Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain

Chronic Neck Pain

This study will be conducted to compare the effect of adding respiratory exercises versus deep neck flexor training to conventional program on pain, cervical ROM, cervical muscle endurance, function, and chest expansion in patients with chronic mechanical neck pain. Sixty-six (66) of both genders ranging in age from 18 to 35 years old, with a history of mechanical neck pain longer than 3 months (chronic neck pain) will be invited to participate in this study. Participants will be randomly assigned into one of the three experimental groups as follow: Group A will receive respiratory exercises in form of diaphragmatic breathing \& respiratory muscle stretch gymnastics plus conventional program. Group B will receive deep neck flexor training in the form of low-load craniocervical flexion using feedback from an air-filled pressure sensor placed behind the neck plus conventional program. Group C (control group) will receive conventional program in form of TENS, infrared, isometric neck strengthening exercises and stretching exercises.

Начало: 10.03.2026 Край: 01.12.2026 Възраст: 18–35 г.

Egypt Cairo University NCT07531537

Recruiting

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Abnormal Uterine Bleeding (AUB) Endometrial Cancer Atypical Endometrial Hyperplasia Endometrial Hyperplasia With Atypia +1

This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.

Начало: 10.03.2026 Край: 24.04.2028 Възраст: от 18 г.

United States Exact Sciences Corporation NCT07544680

Recruiting

Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

Gynecologycal Cancer

The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.

Начало: 10.03.2026 Край: 01.04.2027 Възраст: от 50 г.

United States Wake Forest University Health Sciences NCT07046936

Recruiting Phase 3

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

Trial status: Authorised Change from baseline in the CGI-S score at Week 6., Change from baseline in the MADRS total score at Week 1., Change from baseline in the SHAPS total score at Week 6. Change from baseline in the MADRS total score at Week 6.

Начало: 10.03.2026 Възраст: от 18 г.

Bulgaria, Germany, Poland +1 Xenon Pharmaceuticals Inc. 2025-522775-29-00

Recruiting Phase 1

The clinical trial to study a new drug, AP-2.

ALS and related disorders like frontotemporal dementia and Alexander disease.

Trial status: Authorised

Начало: 10.03.2026 Възраст: 18–64 г.

Spain Molefy Pharma S.L. 2025-524480-21-00

Recruiting Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Progressive Multiple Sclerosis

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

Начало: 10.03.2026 Край: 30.05.2030 Възраст: 18–60 г. Treatment

Australia, France, Italy +5 Hoffmann-La Roche NCT07282574

Recruiting Phase 1

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

Pneumonia, Bacterial

This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.

Начало: 10.03.2026 Край: 24.12.2026 Възраст: 50–64 г. Prevention

Australia GlaxoSmithKline NCT07428759

Recruiting

Effectiveness-Implementation Evaluation of Acute Kidney Injury Decision Support

Acute Kidney Injury

Study Purpose: This study is testing an artificial intelligence (AI)-powered clinical decision support (CDS) system designed to help emergency department (ED) doctors detect and manage acute kidney injury (AKI) earlier. The goal is to see whether the tool improves patient care, clinician decision-making, and hospital outcomes when used in real-world ED settings. Study Design: The AI tool will be gradually introduced at three hospital EDs: Johns Hopkins Hospital (JHH) Bayview Medical Center (BMC) Howard County General Hospital (HCGH) Before the tool is activated, it will run in the background to collect baseline data without influencing care. Once implemented, doctors will receive training, and researchers will track how often the tool is used and whether it improves AKI care. What the Study Measures: Process Outcomes: Does the tool help doctors identify AKI sooner, avoid harmful medications, and improve decision-making about hospitalization? Clinical Outcomes: Does the tool reduce the number and severity of AKI cases and improve kidney-related health outcomes? Implementation Outcomes: Do ED doctors find the tool useful? Does it fit into the ED doctor's workflow without slowing the ED doctor's down? Expected Impact: If successful, the AI tool could be expanded to other hospitals and used to improve early detection and treatment of AKI, reducing kidney complications and improving patient care nationwide.

Начало: 10.03.2026 Край: 01.12.2030 Възраст: от 18 г.

United States Johns Hopkins University NCT06840210

Recruiting Phase 2

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Idiopathic Pulmonary Fibrosis (IPF)

This study will evaluate the impact Nintedanib Solution for Inhalation (AP02) has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) as well as assess its safety and tolerability. Adults 40 years of age or older with IPF who meet the inclusion and exclusion criteria can participate in this study if they are not currently on treatment for IPF, and if treated with oral nintedanib or pirfenidone, have stopped the medication for at least 3 months. Researchers will compare two different doses of AP02 to a placebo (a look-alike substance that contains no drug) to see if AP02 works to treat IPF. Participants are put into 1 of 3 groups randomly, which means by chance and will take AP02 or a placebo two times every day for 12 weeks by using a nebulizer, which is a device that provides medicine to the lungs via inhalation. Participants will visit the office 6 times and receive 1 phone call over a 16-week period. At site visits doctors regularly perform breathing tests that measure how well the lungs are working, give the patient questionnaires and will check the participants' health.

Начало: 10.03.2026 Край: 01.06.2027 Възраст: от 40 г. Treatment

Australia, Canada Avalyn Pharma Inc. NCT07194382

Recruiting Phase 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Lymphoma, Small Lymphocytic

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Начало: 09.03.2026 Край: 01.12.2032 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +12 Eli Lilly and Company NCT07218341

Recruiting Early Phase 1

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Healthy Adult Prostate Cancer

This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled PSMA-targeting tracer or ⁶⁸Ga-labeled ACP3-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.

Начало: 09.03.2026 Край: 01.08.2026 Възраст: от 18 г.

China FindCure Biosciences (ZhongShan) Co., Ltd. NCT07468708

Recruiting

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

Liver Cirrhosis Portal Hypertension

Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Histological modificaitions fo the portal vein wall and haemostatic changes have been described in cirrhotic patients. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated. One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance. Inflammatory phenomena and NETosis may also be involved. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS). During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses. The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients.

Начало: 09.03.2026 Край: 09.06.2027 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT07439939

Recruiting Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy Secondary to Age-related Macular Degeneration

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Начало: 09.03.2026 Край: 22.08.2029 Възраст: от 50 г. Treatment

Australia, United States Novartis Pharmaceuticals NCT07441642

Recruiting Phase 2

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Non-segmental Vitiligo

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

Начало: 09.03.2026 Край: 14.02.2030 Възраст: 18–99 г. Treatment

Australia, Canada, United States Novartis Pharmaceuticals NCT07431177

1 … 30 31 32 33 34 … 222